{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0.52","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The PR response after 4 cycles of induction treatment with pembrolizumab added to lenalidomide and dexamethasone will be estimated by the number of patients who achieve a PR, VGPR, CR, or sCR after 4 cycles divided by the total number of evaluable patients. A PR is defined by the following criteria:\\>\n\n* If present at baseline, ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein or to \\<200 mg/24hrs\\>\n* If the only measurable disease is FLC, a ≥50% reduction in the difference between involved and involved FLC levels\\>\n* If the only measurable disease is BM, a ≥50% reduction in BM PC's (provided the baseline PC's was ≥30%)\\>\n* If present at baseline, ≥50% reduction in the size of soft tissue plasmacytomas\\>\n\nExact binomial 95% confidence intervals for the true success rate will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 25 mg lenalidomide PO daily on days 1-21 and 40 mg dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive 200 mg pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.","id":"OG000","title":"Treatment (Lenalidomide, Dexamethasone, Pembrolizumab)"}],"paramType":"NUMBER","populationDescription":"Only patients that completed 4 cycles of treatment were included in this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to 112 days","title":"Partial Response (PR)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}